title: [Specific features of rehabilitation in patients with gluten-sensitivity celiac disease].
abstract: OBJECTIVE
  To elaborate recommendations for rehabilitation of patients with gluten-sensitivity celiac disease (GCD) on the basis of a long-term follow-up.
  
  
  METHODS
  Eighty-seven patients with GCD were followed up for as long as 31 years. Of those, 72.4% of the patients kept strictly to their gluten-free diet (GFD) throughout the follow-up; 9.2% did not follow the diet periodically; and 18.4% did not at all. The sera from 71 patients were tested for IgA and IgG anti-gliadin antibodies (AGAb) and anti-tissue transglutaminase antibodies (ATTGAb) at as long as 19-year follow-up. AGAb and ATTGAb were estimated by enzyme immunoassay (IMMCO Diagnostics). All the patients underwent endoscopic and histological examinations of the small bowel mucosa (SBM).
  
  
  RESULTS
  To support the validity of keeping to the GFD, the time course of clinical, laboratory, and morphological changes were analyzed in 63 and 24 GFD followers and non-followers, respectively. The GFD non-followers were more frequently found to have diarrheic syndrome, symptoms of malabsorption syndrome, lower serum concentrations of hemoglobin, total protein, iron, and calcium; no SBM structural recovery was seen in any patient. When the GFD was long adhered to, there was also a reduction in detection rates and AGAb and ATTGAb concentrations.
  
  
  CONCLUSIONS
  The adherence to the GFD was ascertained to contribute to fuller rehabilitation in the patients. However, even the patients who had strictly kept to their GFD showed periods of an exacerbation and incomplete SBM structural recovery. Therefore, the rehabilitation system for patients with GCD must involve diagnostic, therapeutic, and organizational measures that promote not only rapid clinical recovery, but also better quality of life in these patients.
authors.forename: E A
authors.initials: EA
authors.lastname: Sabel'nikova
authors.forename: L M
authors.initials: LM
authors.lastname: Krums
authors.forename: A I
authors.initials: AI
authors.lastname: Parfenov
authors.forename: N N
authors.initials: NN
authors.lastname: Vorob'eva
authors.forename: R B
authors.initials: RB
authors.lastname: Gudkova
mesh_terms: D000328:Adult; D001323:Autoantibodies / Q000097:blood*; D002446:Celiac Disease / Q000276:immunology / Q000534:rehabilitation*; D055050:Diet, Gluten-Free; D005260:Female; D005500:Follow-Up Studies; D005983:Glutens / Q000276:immunology* / Q000378:metabolism; D006801:Humans; D007413:Intestinal Mucosa / Q000276:immunology* / Q000473:pathology; D008297:Male; D016896:Treatment Outcome
chemical_list: D001323:Autoantibodies; D005983:Glutens